Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Enveric Biosciences, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 253.2K | 234.2K | −19.1K (−7.5%) |
| Value | $344.7K | $283.2K | −$61.5K (−17.8%) |
New holders (4)
Institutions that held Enveric Biosciences, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 37,012 | $44.8K | 0.00% |
| Morgan Stanley | 13,020 | $15.8K | 0.00% |
| Bank of America Corp | 24 | $29 | 0.00% |
| Jones Financial Companies LLLP | 1 | $1 | 0.00% |
Sold out (5)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| HRT Financial LP | 40,625 | $56.0K |
| Citadel Advisors LLC | 20,060 | $27.9K |
| FMR LLC | 3,426 | $4.76K |
| Headlands Technologies LLC | 110 | $153 |
| Barclays PLC | 30 | $42 |